Newsroom | 11905 results

AZUSA, Calif.--(BUSINESS WIRE)--OneLegacy will honor 19 Southern Californians whose lives have been touched by the power of organ, eye, and tissue donation on the 2026 OneLegacy Donate Life Rose Parade® float, themed “Treasure Every Moment Together.” The announcement was made at a press event that took place earlier this month at Rosemont Pavilion in Pasadena, where the float is being decorated with dried organic materials by Artistic Entertainment Services (AES) staff and volunteers, ahead of...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w...

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health has received approval to launch Long Island’s first adult pancreas transplant program, according to a letter from the New York State Department of Health (DOH). The Northwell Transplant Institute at North Shore University Hospital (NSUH) recently hosted a site visit with DOH officials, the final hurdle before opening the program to new patients. Northwell’s pancreas program will open access to patients across the greater New York and southern C...

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a pilot clinical trial to examine the safety and efficacy of TETRANITE®, the company’s regenerative bone adhesive, to perform dental ridge augmentation procedures without the need for ancillary containment devices like membranes or meshes or fixation aids like tacks and screws. “The ability for the product to adhere to the surrounding bony walls of a site tha...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. “These appointments represent a significant milestone as Adagio prepares for commercializat...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity award...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth postponement of STAAR’s Special Meeting of Shareholders (the “Special Meeting”) in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). The Special Meeting, which was originally scheduled to be held on October 23, 2...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the “Special Meeting”). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to Janua...

LEOBENDORF, Autriche--(BUSINESS WIRE)--Croma-Pharma, acteur mondial de la médecine esthétique mini-invasive, est fier d'annoncer le lancement de son nouveau dispositif médical qui est utilisé pour la préparation du plasma riche en plaquettes (PRP) autologue | la fibrine riche en plaquettes fluide (PRF fluide).1 Ce lancement représente un progrès continu dans la mission de Croma consistant à fournir aux professionnels de la santé des outils de pointe pour leur pratique. Avec sa conception innova...

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma, líder mundial en medicina estética mínimamente invasiva, tiene el orgullo de anunciar la presentación de su nuevo dispositivo médico para preparar plasma rico en plaquetas (PRP) autólogo | Fibrina rica en plaquetas líquida (FRP líquida). Esta presentación representa el progreso continuo en la misión de Croma: brindarles a los profesionales sanitarios las herramientas de última generación que necesitan para su práctica. Gracias a su diseño inno...